ストックスクリーナーアプリを入手
83.48
0.07%
-0.05
前日終値:
$83.53
開ける：
$83.52
24時間の取引高:
3.19M
Relative Volume:
1.28
時価総額：
$8.84B
収益：
$18.07M
当期純損益:
$-496.39M
株価収益率:
-16.26
EPS:
-5.1333
ネットキャッシュフロー:
$-419.52M
1週間 パフォーマンス:
+115.81%
1か月 パフォーマンス:
+149.33%
6か月 パフォーマンス:
+56.79%
1年 パフォーマンス:
+184.22%
1日の値動き範囲:
$83.47
$83.57
1週間の範囲:
$39.83
$83.63
52週間の値動き範囲:
$25.83
$83.63
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
名前
Crinetics Pharmaceuticals Inc
セクター
電話
858-450-6464
住所
6055 LUSK BLVD., SAN DIEGO, CA
Compare CRNX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
83.48 | 8.84B | 18.07M | -496.39M | -419.52M | -5.1333 |
VRTX
Vertex Pharmaceuticals Inc
|
520.08 | 132.55B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.10 | 70.90B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.84 | 57.21B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
317.15 | 42.94B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
192.86 | 40.49B | 742.00K | -1.37B | -1.07B | -7.0731 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-12 | アップグレード | Goldman | Neutral → Buy |
| 2025-07-10 | 開始されました | Goldman | Neutral |
| 2025-03-25 | 開始されました | Stifel | Buy |
| 2025-02-11 | 開始されました | TD Cowen | Buy |
| 2025-02-04 | 開始されました | Wolfe Research | Peer Perform |
| 2025-01-22 | アップグレード | Jefferies | Hold → Buy |
| 2024-03-06 | 開始されました | Citigroup | Buy |
| 2024-01-16 | 開始されました | Morgan Stanley | Overweight |
| 2023-12-21 | 開始されました | Jefferies | Hold |
| 2023-11-20 | 再開されました | JP Morgan | Overweight |
| 2023-10-24 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-08-31 | 開始されました | Oppenheimer | Outperform |
| 2023-04-24 | 開始されました | Piper Sandler | Overweight |
| 2023-03-30 | 開始されました | Robert W. Baird | Outperform |
| 2021-11-30 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-11-23 | 開始されました | Evercore ISI | Outperform |
| 2021-06-18 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-12-23 | 開始されました | ROTH Capital | Buy |
| 2019-02-14 | 開始されました | H.C. Wainwright | Buy |
| 2018-08-13 | 開始されました | JP Morgan | Neutral |
| 2018-08-13 | 開始されました | Leerink Partners | Outperform |
| 2018-08-13 | 開始されました | Piper Jaffray | Overweight |
すべてを表示
Crinetics Pharmaceuticals Inc (CRNX) 最新ニュース
Vertex to acquire Crinetics in deal worth around $10.0bn - PMLiVE
Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil - BioSpace
Viking Therapeutics (VKTX) Draws Takeover Focus After Vertex's $10 Billion Crinetics Deal - Yahoo Finance
Vertex Is Paying a 102% Premium to Acquire Crinetics for $10 Billion. Here's Whether the Deal Is Worth It. - The Globe and Mail
Vertex Is Paying a 102% Premium to Acquire Crinetics for $10 Billion. Here's Whether the Deal Is Worth It. - The Motley Fool
The $10B Integration Problem Vertex Hasn’t Solved Yet - The Clinical Trial Vanguard
Narrow-Moat Vertex's Strong CF Cash Flows Support Expansion Into Endocrinology Via Crinetics - Morningstar
Vertex Is Buying Crinetics for $10 Billion. Here's What Investors Need to Know. - The Motley Fool
Why Did CRNX, D, BCRX Stocks Surge To 52-Week Highs Today? - Yahoo Finance
Why Crinetics Stock Doubled After Vertex’s $10 Billion Buyout - BeInCrypto
Vertex to acquire Crinetics in $10 billion rare-disease push - MSN
Investigation launched into Crinetics Pharma bo... - Pluang
Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A booms - The Boston Globe
Crinetics Pharmaceuticals director sells $120,000 in stock - Investing.com
Vertex Pharma’s Growth Strategy Leads to Its Biggest-Ever M&A Deal - MedCity News
Form 4 Crinetics Pharmaceuticals Inc For: 7 July By Investing.com - Investing.com India
Vertex Eyes Expansion Beyond Cystic Fibrosis with Planned $10B Crinetics Buyout - Genetic Engineering and Biotechnology News
Crinetics Pharmaceuticals director sells $120,000 in stock By Investing.com - Investing.com Canada
Crinetics (CRNX) director sells 3,000 shares at $40 in planned trade - Stock Titan
Vertex (VRTX) Is Buying Crinetics For $10 Billion And Entering Endocrinology - Yahoo Finance
Eli Lilly price target boost, Vertex-Crinetics deal, Meta's new social media lawsuit - Yahoo Finance
The Changing Reality of Pharmaceutical Commercialization | PharmExec - Pharmaceutical Executive
Vertex to buy Crinetics in an all-cash deal valued at $10 billion - CNBC
Vertex Pays $10 Billion to Enter Rare Endocrine Disease - TradingView
Vertex's $10B Crinetics deal marks its clearest step yet toward biopharma's top ranks - Endpoints News
This Biotech Stock Is Soaring 99% After Vertex Agrees to Takeover Deal - Barron's
Vertex to Acquire Crinetics Pharmaceuticals for $10 Billion - Pharmaceutical Executive
CRNX Soars On $10B Vertex Buyout As Trading Dynamics Shift - StocksToTrade
CRNX Downgraded by Jones Trading -- Rating Changed to Hold - GuruFocus
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Crinetics Pharmaceuticals Cut to Hold From Buy by Jones Trading - Moomoo
Crinetics Pharmaceuticals (CRNX) Agreed To A $10 Billion All Cash Sale To Vertex - simplywall.st
CRNX Soars On Vertex’s $10B Buyout And Tight Trading Range - StocksToTrade
Endocrinology becomes Vertex’s fifth pillar with $10B Crinetics buy - BioWorld News
SpaceX Joins Nasdaq 100; Crinetics Pharmaceuticals Soars on Buyout | Stock Movers - marketscreener.com
Compass says depression drug has long-lasting benefits - STAT
Crinetics (CRNX) Soars 98.8% to Reach $83.55 - GuruFocus
CRNX Downgraded by Oppenheimer -- Rating Changed to Perform - GuruFocus
Vertex Pharmaceuticals (VRTX) Announces Strategic Merger with Cr - GuruFocus
Vertex makes largest ever acquisition with $10bn Crinetics deal - BioXconomy
Crinetics Pharmaceuticals stock hits all-time high at 83.59 USD By Investing.com - Investing.com Nigeria
Jones Trading downgrades Crinetics stock rating on Vertex acquisition - Investing.com
Crinetics Pharmaceuticals stock hits all-time high at 83.59 USD - Investing.com
Vertex Pharmaceuticals to acquire Crinetics in a $10 billion deal, sending the latter's share price nearly doubling - 富途牛牛
Crinetics shares surge after Vertex agrees to $10B cash buyout - Invezz
Crinetics Pharmaceuticals Stock (CRNX) Opinions on Vertex Acquisition - Quiver Quantitative
CRNX Stock Soars On $10B Vertex Takeover Deal - StocksToTrade
Crinetics Acquisition Creates A ‘Fifth Commercial Pillar’ For Vertex, Says Analyst – Why HC Wainwright Sees A 24% Upside Potential In VRTX Stock - Yahoo Finance
Vertex Pharmaceuticals buying Crinetics for $10 billion - qz.com
CRINETICS PHARMACEUTICALS, INC. (CRNX) - MSN
Crinetics (CRNX) Stock Surges Ahead of Vertex's $10 Billion Acqu - GuruFocus
Crinetics Pharmaceuticals Inc (CRNX) 財務データ
収益
当期純利益
現金流量
EPS
1.01%
5.65%
大文字化:
|
ボリューム (24 時間):